Robeco Institutional Asset Management B.V. Raises Position in IDEXX Laboratories, Inc. $IDXX

Key Points

• Robeco Institutional Asset Management B.V. increased its stake in IDEXX Laboratories, Inc. by 39.8% during the second quarter, holding approximately 207,228 shares valued at $111 million.
• Wall Street analysts have set a consensus price target of $656.50 for IDEXX Laboratories, with varying ratings from "buy" to "hold" based on recent evaluations.
• Insider activity shows significant sales, with two executives selling a total of 3,387 shares near the stock's peak prices, indicating possible profit-taking among insiders.

Robeco Institutional Asset Management B.V. lifted its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 39.8% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 207,228 shares of the company's stock after purchasing an additional 58,991 shares during the quarter. Robeco Institutional Asset Management B.V. owned about 0.26% of IDEXX Laboratories worth $111,145,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Heritage Financial Services LLC acquired a new stake in IDEXX Laboratories in the 2nd quarter worth about $220,000. Madrona Financial Services LLC acquired a new stake in shares of IDEXX Laboratories in the second quarter worth approximately $224,000. Ninety One SA PTY Ltd boosted its position in shares of IDEXX Laboratories by 3.6% in the second quarter. Ninety One SA PTY Ltd now owns 6,222 shares of the company's stock worth $3,337,000 after acquiring an additional 214 shares during the last quarter. Pacific Point Advisors LLC grew its holdings in IDEXX Laboratories by 5.2% in the second quarter. Pacific Point Advisors LLC now owns 3,636 shares of the company's stock valued at $1,950,000 after purchasing an additional 179 shares during the period. Finally, Institute for Wealth Management LLC. acquired a new position in IDEXX Laboratories during the second quarter worth approximately $219,000. 87.84% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the stock. Jefferies Financial Group started coverage on shares of IDEXX Laboratories in a report on Tuesday, July 1st. They issued a "buy" rating and a $625.00 price target on the stock. Stifel Nicolaus set a $640.00 target price on IDEXX Laboratories in a report on Monday, August 4th. BTIG Research upped their price target on IDEXX Laboratories from $545.00 to $785.00 and gave the stock a "buy" rating in a research note on Tuesday, August 5th. UBS Group started coverage on IDEXX Laboratories in a report on Wednesday. They issued a "neutral" rating and a $720.00 price objective on the stock. Finally, Wall Street Zen cut IDEXX Laboratories from a "strong-buy" rating to a "buy" rating in a report on Sunday, September 28th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and four have issued a Hold rating to the company's stock. According to data from MarketBeat, IDEXX Laboratories presently has an average rating of "Moderate Buy" and a consensus price target of $656.50.

Insider Activity

In other IDEXX Laboratories news, EVP Nimrata Hunt sold 1,200 shares of the stock in a transaction that occurred on Monday, August 11th. The stock was sold at an average price of $656.53, for a total transaction of $787,836.00. Following the transaction, the executive vice president owned 16,807 shares of the company's stock, valued at $11,034,299.71. This trade represents a 6.66% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director M Anne Szostak sold 2,187 shares of the business's stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $647.33, for a total value of $1,415,710.71. Following the completion of the sale, the director owned 262 shares of the company's stock, valued at $169,600.46. This trade represents a 89.30% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 54,057 shares of company stock valued at $34,293,468 over the last three months. Company insiders own 0.98% of the company's stock.

IDEXX Laboratories Stock Up 2.2%

Shares of NASDAQ:IDXX opened at $633.84 on Friday. The company has a current ratio of 1.11, a quick ratio of 0.79 and a debt-to-equity ratio of 0.31. The company has a fifty day simple moving average of $633.20 and a 200 day simple moving average of $533.33. The firm has a market cap of $50.71 billion, a PE ratio of 52.78, a price-to-earnings-growth ratio of 4.02 and a beta of 1.58. IDEXX Laboratories, Inc. has a 12-month low of $356.14 and a 12-month high of $688.12.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last released its earnings results on Monday, August 4th. The company reported $3.63 earnings per share for the quarter, topping the consensus estimate of $3.28 by $0.35. IDEXX Laboratories had a net margin of 24.41% and a return on equity of 64.42%. The company had revenue of $1.11 billion during the quarter, compared to the consensus estimate of $1.06 billion. During the same quarter in the previous year, the firm earned $2.44 EPS. The company's revenue was up 10.6% on a year-over-year basis. IDEXX Laboratories has set its FY 2025 guidance at 12.400-12.760 EPS. On average, equities research analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.